Latest / Applied Clinical Trials
ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership
In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & Johnson’s positive Phase IIb results for nipocalimab in systemic lupus erythematosus, and break down a new multibillion-dollar research and licensing agreement between Nimbus Therapeutics and Eli Lilly targeting oral obesity treatments.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.